Erasca upgraded by BofA Securities with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for ERAS
Across the 21 sessions after earlier ERAS headlines, the stock closed higher 12 times and lower 9 times, with a median move of 4.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ERAS | SPY |
|---|---|---|---|
| May 27, 2026 | Erasca to Present at the Jefferies Global Healthcare Conference | +8.4% | -0.0% |
| May 12, 2026 | Erasca Reports First Quarter 2026 Business Updates and Financial Results | -0.6% | -0.2% |
| May 11, 2026 | Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab) | +3.2% | +0.2% |
| May 6, 2026 | Erasca to Present at the Bank of America Securities Health Care Conference | +9.1% | +1.4% |
| Apr 28, 2026 | Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | -48.3% | -0.5% |
| Apr 27, 2026 | Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 | -10.9% | +0.2% |
Quantisnow market dataNASDAQ
ERAS
Erasca Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for ERAS
Full ERAS profile on Quantisnow Follow ERAS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time